IMPACT OF CANNABINOIDS ON COGNITION, MOOD, SLEEP AND QUALITY OF LIFE IN LONG-LIVED PATIENTS DIAGNOSED WITH MILD TO MODERATE DEMENTIA SYNDROME.
Cannabinoids; CBD; THC; Dementia; Cognition; Sleep; Mood; Quality of life;
Life expectancy and consequently, the number of dementia cases has increased globally, demanding new therapeutic approaches. Tetrahydrocannabinol (THC) and cannabidiol (CBD), cannabinoids derived from Cannabis sativa, exhibit neuroprotective properties and modulate mood and sleep. This experimental, descriptive, quantitative, and longitudinal study evaluated the impact of Cannabis sativa formulations rich in CBD and THC on cognition, mood, sleep, and quality of life in 19 elderly patients diagnosed with mild to moderate dementia of various etiologies. Dosages were individually adjusted under medical supervision. Participants were assessed using validated psychometric scales before the initiation of treatment and after four months. The results indicated significant improvement in neuropsychiatric symptoms, quality of life, and life satisfaction. Appropriate statistical tests were applied based on data distribution, with corrections for multiple comparisons and canonical correlation analysis. The findings support the hypothesis of the safety and therapeutic potential of cannabinoid use in elderly patients with dementia in an outpatient setting. Despite these promising results, large-scale clinical trials with more rigorous methodologies and expanded scientific criteria are essential to validate these preliminary findings and establish more precise and evidence-based therapeutic guidelines for clinical practice.